Good morning, everyone, and welcome to another working week. We hope the weekend respite was somehow relaxing and refreshing. After all, a break is a break. Now, though, the predictable round of Zoom and Skype meetings has returned. So time to get ready and we are doing so by brewing a few cups of delicious stimulation — maple bourbon, in this instance. Feel free to join us. Remember, no prescription is required. Meanwhile, here are a few tidbits to get you going on your own journey. Hope you have a useful day and do keep in touch …

Amid escalating concerns over antibiotic resistance, several big drug makers are creating a new $1 billion for-profit venture to acquire or invest in small antibiotic companies and their nascent products, according to STAT. The effort will be announced on July 9 by the chief executive officers at Pfizer (PFE), Merck (MRK), Eli Lilly (LLY), and Novo Nordisk (NVO), among others. Billed as a new initiative to take on “the antibiotic innovation challenge,” the venture will have assistance from the World Health Organization and the European Investment Bank.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • Given that Remdesivir is to be used when patients have reached the ICU, if 5 days at $470 / day saves / prevents 5 additional days in the ICU, it seems to be more than worth the price. (Givens and if’s included…)

Comments are closed.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy